Clinical Trial Update: Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease [Phase 2]

View source ↗

Summary

Phase 2 study evaluating vorinostat to induce fetal hemoglobin in sickle cell disease was terminated; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Vorinostat (Zolinza) (vorinostat)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Sickle Cell Disease, Sickle Cell Anemia | Phase 2 | Status: TERMINATED | Results posted: 2015-10-08